TDMS Study 05096-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
O-CHLOROBENZALMALONONITRILE (CS-2)
NTP Experiment-Test: 05096-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 05:17:37
Facility: Battelle Northwest
Chemical CAS #: 2698-41-1
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05096-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-CHLOROBENZALMALONONITRILE (CS-2) Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 05:17:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.75 MG/ 1.5 MG/
M3 M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Dead 9 5 7
Moribund 8 5 3
Survivors
Terminal Sacrifice 33 40 40
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (10) (47)
Gallbladder (42) (5) (40)
Intestine Large, Cecum (44) (7) (43)
Leiomyosarcoma 1 (14%)
Intestine Large, Colon (46) (9) (44)
Intestine Large, Rectum (47) (9) (45)
Intestine Small, Duodenum (43) (7) (44)
Intestine Small, Ileum (44) (9) (44)
Intestine Small, Jejunum (43) (9) (43)
Liver (50) (15) (49)
Hepatocellular Carcinoma 7 (14%) 1 (7%) 4 (8%)
Hepatocellular Carcinoma, Multiple 1 (7%) 2 (4%)
Hepatocellular Adenoma 4 (8%) 2 (13%) 3 (6%)
Mesentery (4) (1)
Pancreas (50) (11) (49)
Salivary Glands (50) (10) (49)
Stomach, Forestomach (48) (48) (47)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 2 (4%) 4 (8%)
Stomach, Glandular (49) (48) (47)
Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (10) (49)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05096-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-CHLOROBENZALMALONONITRILE (CS-2) Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 05:17:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.75 MG/ 1.5 MG/
M3 M3
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (10) (49)
Osteosarcoma, Metastatic, Bone 1 (2%)
Adrenal Gland, Medulla (49) (10) (48)
Pheochromocytoma Benign 2 (4%)
Islets, Pancreatic (50) (9) (48)
Pituitary Gland (47) (46) (46)
Pars Distalis, Adenoma 13 (28%) 5 (11%) 1 (2%)
Pars Intermedia, Adenoma 3 (7%)
Thyroid Gland (49) (49) (49)
Follicular Cell, Adenoma 2 (4%) 2 (4%) 2 (4%)
Follicular Cell, Adenoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (20) (49)
Adenoma 1 (2%)
Hemangioma 1 (5%)
Teratoma 1 (2%) 1 (2%)
Teratoma Malignant 1 (5%)
Uterus (49) (15) (48)
Hemangioma 1 (2%) 1 (7%) 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyoma 1 (2%)
Polyp, Adenoid 1 (2%)
Polyp Stromal 2 (4%) 1 (7%)
Sarcoma Stromal 1 (7%)
Vagina (1)
Polyp 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (10) (49)
Lymph Node (50) (15) (48)
Teratoma NOS, Metastatic, Ovary 1 (7%)
Pancreatic, Sarcoma 1 (2%)
Lymph Node, Bronchial (48) (11) (46)
Lymph Node, Mandibular (44) (11) (38)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Page 3
NTP Experiment-Test: 05096-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-CHLOROBENZALMALONONITRILE (CS-2) Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 05:17:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.75 MG/ 1.5 MG/
M3 M3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Spleen (50) (19) (49)
Sarcoma 1 (2%)
Thymus (46) (10) (46)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (45) (10) (47)
Adenocarcinoma 3 (7%) 1 (10%)
Skin (50) (17) (49)
Fibrosarcoma 1 (2%)
Hemangiosarcoma 1 (2%)
Papilloma 1 (2%)
Sarcoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (12) (49)
Cranium, Osteosarcoma 1 (8%) 1 (2%)
Vertebra, Osteosarcoma 1 (2%)
Skeletal Muscle (1)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (11) (49)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (10) (47)
Lung (50) (17) (49)
Adenocarcinoma, Metastatic, Harderian Gland 2 (4%) 1 (2%)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
Alveolar/Bronchiolar Adenoma 4 (8%) 2 (12%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%)
Carcinoma, Metastatic, Liver 2 (4%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Bronchus, Alveolus, Adenoma 1 (6%)
Mediastinum, Hemangioma 1 (6%)
Nose (50) (49) (49)
Adenocarcinoma, Metastatic, Harderian Gland 1 (2%)
Trachea (50) (10) (48)
Page 4
NTP Experiment-Test: 05096-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-CHLOROBENZALMALONONITRILE (CS-2) Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 05:17:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.75 MG/ 1.5 MG/
M3 M3
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (2) (1)
Adenocarcinoma 2 (50%) 1 (100%)
Adenoma 2 (50%) 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (13) (49)
Osteosarcoma, Metastatic, Bone 1 (2%)
Urinary Bladder (48) (8) (47)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant 2 (4%)
Lymphoma Malignant Histiocytic 2 (4%) 3 (6%) 1 (2%)
Lymphoma Malignant Mixed 6 (12%) 9 (18%) 4 (8%)
Lymphoma Malignant Undifferentiated Cell 11 (22%) 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05096-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-CHLOROBENZALMALONONITRILE (CS-2) Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 05:17:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.75 MG/ 1.5 MG/
M3 M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 46 27 27
Total Primary Neoplasms 80 43 33
Total Animals with Benign Neoplasms 23 17 13
Total Benign Neoplasms 37 23 15
Total Animals with Malignant Neoplasms 35 17 16
Total Malignant Neoplasms 43 20 18
Total Animals with Metastatic Neoplasms 9 1 1
Total Metastatic Neoplasm 12 1 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05096-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-CHLOROBENZALMALONONITRILE (CS-2) Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 05:17:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.75 MG/ 1.5 MG/
M3 M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Dead 7 4 5
Moribund 5 4 5
Survivors
Terminal Sacrifice 38 42 40
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (39) (5) (40)
Intestine Small, Duodenum (44) (5) (44)
Polyp Adenomatous 1 (20%)
Intestine Small, Ileum (43) (3) (44)
Intestine Small, Jejunum (44) (2) (47)
Adenocarcinoma 1 (2%)
Liver (49) (19) (50)
Carcinoma, Metastatic, Lung 1 (2%)
Hemangioma 1 (2%)
Hemangioma, Multiple 1 (2%)
Hemangiosarcoma, Multiple 1 (2%)
Hepatocellular Carcinoma 11 (22%) 5 (26%) 5 (10%)
Hepatocellular Carcinoma, Multiple 3 (6%) 2 (11%) 3 (6%)
Hepatocellular Adenoma 3 (6%) 8 (42%) 5 (10%)
Hepatocellular Adenoma, Multiple 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (1) (1)
Sarcoma, Metastatic, Stomach 1 (100%)
Pancreas (49) (7) (50)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Salivary Glands (49) (7) (50)
Stomach, Forestomach (47) (45) (49)
Sarcoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (49) (49) (48)
Sarcoma, Metastatic, Stomach 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05096-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-CHLOROBENZALMALONONITRILE (CS-2) Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 05:17:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.75 MG/ 1.5 MG/
M3 M3
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (8) (50)
Carcinoma, Metastatic, Lung 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (7) (49)
Adenoma 1 (2%)
Adrenal Gland, Medulla (49) (7) (49)
Pituitary Gland (46) (7) (46)
Pars Distalis, Adenoma 1 (14%)
Thyroid Gland (48) (7) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (46) (7) (49)
Prostate (48) (7) (49)
Seminal Vesicle (47) (9) (49)
Testes (48) (7) (50)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (7) (50)
Lymph Node (48) (9) (47)
Mediastinal, Adenocarcinoma, Metastatic, Lung 1 (11%)
Lymph Node, Bronchial (47) (5) (43)
Carcinoma, Metastatic, Lung 2 (4%)
Lymph Node, Mandibular (42) (4) (35)
Spleen (49) (8) (50)
Hemangiosarcoma 2 (4%)
Thymus (38) (5) (43)
Carcinoma, Metastatic, Lung 1 (3%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05096-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-CHLOROBENZALMALONONITRILE (CS-2) Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 05:17:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.75 MG/ 1.5 MG/
M3 M3
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (13) (50)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (49) (8) (50)
Cranium, Adenocarcinoma, Metastatic, Lung 1 (13%)
Rib, Carcinoma, Metastatic, Lung 1 (13%)
Skeletal Muscle (2)
Diaphragm, Carcinoma, Metastatic, Lung 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (49) (50)
Adenocarcinoma 1 (2%)
Alveolar/Bronchiolar Adenoma 7 (14%) 7 (14%) 9 (18%)
Alveolar/Bronchiolar Carcinoma 5 (10%) 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 4 (8%) 2 (4%) 1 (2%)
Nose (50) (47) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (6) (2) (2)
Adenoma 6 (100%) 2 (100%) 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (49) (50)
Adenocarcinoma, Metastatic, Lung 1 (2%)
Carcinoma, Metastatic, Liver 1 (2%)
Carcinoma, Metastatic, Lung 1 (2%)
Urinary Bladder (48) (7) (49)
Page 9
NTP Experiment-Test: 05096-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-CHLOROBENZALMALONONITRILE (CS-2) Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 05:17:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.75 MG/ 1.5 MG/
M3 M3
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%)
Lymphoma Malignant Mixed 1 (2%) 3 (6%) 1 (2%)
Lymphoma Malignant Undifferentiated Cell 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05096-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-CHLOROBENZALMALONONITRILE (CS-2) Date: 09/13/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 05:17:37
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.75 MG/ 1.5 MG/
M3 M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 31 24 30
Total Primary Neoplasms 46 31 37
Total Animals with Benign Neoplasms 18 17 17
Total Benign Neoplasms 20 19 20
Total Animals with Malignant Neoplasms 22 11 15
Total Malignant Neoplasms 26 12 17
Total Animals with Metastatic Neoplasms 6 3 3
Total Metastatic Neoplasm 12 6 5
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 61537-61537/61537
--multipart-boundary--